Table 4 ADCs under clinical investigation for the treatment of GC
Name or ID | Targets | Phase | NCT identifier |
|---|---|---|---|
EO-3021 | CLDN18.2 | Phase I | NCT05980416 |
LCB84 | TROP-2 | Phase I/II | NCT05941507 |
RC48 | HER-2 | Phase I | NCT05514158 |
AZD0901 | VEGF | Phase II | NCT06219941 |
TORL-2-307 | unnamed | Phase I | NCT05156866 |
IKS014 | HER-2 | Phase I | NCT05872295 |
AZD5305 | PARP1 | Phase I/II | NCT04644068 |
BDC-1001 | HER-2 | Phase I/II | NCT04278144 |
Datopotamab-Deruxtecan | TROP2 | Phase I/II | NCT05460273 |
MRG002 | HER-2 | Phase I/II | NCT04492488 |
Trastuzumab deruxtecan | HER-2 | Phase II | NCT04014075 |
SKB264 | TROP2 | Phase I/II | NCT04152499 |
Datopotamab deruxtecan | TROP2 | Phase II | NCT05489211 |
Trastuzumab Emtansine | HER-2 | Phase II | NCT04439110 |
SBT6050 | HER-2 | Phase I | NCT04460456 |
Trastuzumab Emtansine | HER-2 | Phase II | NCT02465060 |